Dx & Vx Past Earnings Performance
Past criteria checks 0/6
Dx & Vx's earnings have been declining at an average annual rate of -9.9%, while the Biotechs industry saw earnings growing at 16.6% annually. Revenues have been growing at an average rate of 52.2% per year.
Key information
-9.9%
Earnings growth rate
2.1%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 52.2% |
| Return on equity | -153.2% |
| Net Margin | -66.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Market Cool On Dx & Vx Co., Ltd.'s (KOSDAQ:180400) Revenues Pushing Shares 39% Lower
Jul 15
Dx & Vx Co., Ltd. (KOSDAQ:180400) Might Not Be As Mispriced As It Looks After Plunging 37%
May 31Investors Give Dx & Vx Co., Ltd. (KOSDAQ:180400) Shares A 25% Hiding
Mar 18Dx & Vx (KOSDAQ:180400) Is Carrying A Fair Bit Of Debt
Mar 08Revenue & Expenses Breakdown
How Dx & Vx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 48,192 | -32,249 | 20,763 | 4,752 |
| 31 Dec 23 | 46,745 | -27,482 | 18,400 | 3,331 |
| 30 Sep 23 | 44,301 | -16,575 | 13,694 | 2,302 |
| 30 Jun 23 | 42,121 | -11,648 | 11,895 | 927 |
| 31 Mar 23 | 35,144 | -4,268 | 7,014 | 1,097 |
| 31 Dec 22 | 32,184 | -1,370 | 6,001 | 792 |
| 31 Mar 22 | 11,463 | -5,987 | 3,563 | 818 |
| 31 Dec 21 | 7,470 | -6,125 | 3,436 | 647 |
| 30 Sep 21 | 8,864 | -3,599 | 3,019 | 1,823 |
| 30 Jun 21 | 8,804 | -3,353 | 3,082 | 1,823 |
| 31 Mar 21 | 8,170 | -4,166 | 3,305 | 1,823 |
| 31 Dec 20 | 7,696 | -6,403 | 4,322 | 1,823 |
| 30 Sep 20 | 6,385 | -12,711 | 5,204 | 849 |
| 30 Jun 20 | 6,387 | -13,547 | 6,077 | 849 |
| 31 Mar 20 | 5,717 | -15,230 | 5,867 | 849 |
| 31 Dec 19 | 5,753 | -17,086 | 6,357 | 849 |
| 30 Sep 19 | 5,758 | -10,381 | 7,330 | 745 |
| 30 Jun 19 | 5,717 | -14,077 | 6,605 | 745 |
| 31 Mar 19 | 5,599 | -13,332 | 7,202 | 579 |
| 31 Dec 18 | 5,305 | -11,348 | 6,120 | 745 |
| 30 Sep 18 | 4,947 | -12,779 | 6,707 | 193 |
| 30 Jun 18 | 4,703 | -7,292 | 5,606 | 362 |
| 31 Dec 17 | 4,670 | -3,743 | 3,046 | 615 |
Quality Earnings: A180400 is currently unprofitable.
Growing Profit Margin: A180400 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A180400 is unprofitable, and losses have increased over the past 5 years at a rate of 9.9% per year.
Accelerating Growth: Unable to compare A180400's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A180400 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (41.1%).
Return on Equity
High ROE: A180400 has a negative Return on Equity (-153.18%), as it is currently unprofitable.